GLP-1 demand is soaring. 2 Stocks that could benefit from this (hint: Not Eli Lilly or Novo Nordisk) The Motley Fool 4d The Motley Fool 4d
Eli Lilly's GLP-1 pricing problem is actually a growth opportunity The Motley Fool 5d The Motley Fool 5d
Why this growth stock manager likes both the AI trade and Eli Lilly MorningStar.com 6d MorningStar.com 6d
Eli Lilly is building a weight loss drug for every kind of patient The Motley Fool 3d The Motley Fool 3d
Top Biotech Gainers: Fdmt, Oabi, Acxp Rally On Pipeline And Regulatory News RTT News 20:02 Mon, 17 Aug
Leal Therapeutics Announces $30 Million Series A Extension and Initiation of Phase 1b/2a Clinical Trial of Ltx-001 in Schizophrenia PR Newswire (Press Release) 14:07 Mon, 17 Aug
Juvena Therapeutics Appoints Julie Anne Smith as Chief Executive Officer Business Wire (Press Release) 13:25 Mon, 17 Aug
OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company Business Wire (Press Release) 11:03 Mon, 17 Aug